Journal
FRONTIERS IN PHARMACOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.684162
Keywords
pharmacogenomic; NSAID (non-steroidal anti-inflammatory drug); gastrointestinal toxicities; aspirin; adverse drug reaction
Categories
Funding
- Medical Research Council grant for the Center for Drug Safety Science, University of Liverpool [MR/L006758/1]
- MRC [MR/L006758/1, MR/S000933/1] Funding Source: UKRI
Ask authors/readers for more resources
NSAIDs are commonly used drugs for pain and inflammation, but chronic use can lead to serious gastrointestinal adverse reactions. Some clinical and genetic predisposing factors have been identified, but further research is needed to determine relevant genetic and non-genetic markers for NSAID-induced peptic ulceration.
Non-steroidal anti-inflammatory drugs (NSAIDs) are a group of drugs which are widely used globally for the treatment of pain and inflammation, and in the case of aspirin, for secondary prevention of cardiovascular disease. Chronic non-steroidal anti-inflammatory drug use is associated with potentially serious upper gastrointestinal adverse drug reactions (ADRs) including peptic ulcer disease and gastrointestinal bleeding. A few clinical and genetic predisposing factors have been identified; however, genetic data are contradictory. Further research is needed to identify clinically relevant genetic and non-genetic markers predisposing to NSAID-induced peptic ulceration.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
